摘要
目的:探讨GemOx方案(吉西他滨联合奥沙利铂)治疗晚期复发转移卵巢癌的疗效及不良反应。方法:共入组22例患者,其中铂类敏感复发转移12例,铂类耐药复发转移10例。所有患者均予吉西他滨1000mg/m2第1,8天静脉给药;奥沙利铂130mg/m2,第1天静脉给药。3周为1周期,每个患者至少接受2周期化疗用药。每2个周期后评价疗效、临床受益反应及不良反应。结果:共完成82个化疗周期,可评价疗效的21例,有效率为31.8%,铂类敏感患者中,有效率为41.7%,铂类耐药为20.0%;临床受益反应率为57.1%;主要毒性反应为骨髓抑制和神经毒性,白细胞减少15例(68.2%),血小板减少16例(72.7%),神经毒性、感觉异常达71.4%。结论:GemOx方案治疗晚期复发转移卵巢癌患者是有效的,毒性反应可以耐受,生存质量明显提高。
Objective： To evaluate the effects of gemcitabine and oxaliplatin （GemOx） on recurrent advanced ovarian carcinoma and its adverse reactions. Methods： A total of 22 patients with recurrent advanced ovarian carcinoma were enrolled, including 12 patients of platinum-sensitive and 10 patients of platinum-resistant. All patients were treated with gemcitabine 1 000 mg/m2 intravenously at 1, 8 days and oxaliplatin 130 mg/m2 intravenously at first day ; 3 weeks was 1 cycle ; each patient received at least 2 cycles of chemotherapy. Efficacy, clinical benefit response and adverse reactions were evaluated every two cycles. Results： A total of 82 cycles of chemotherapy were completed; 21 cases received evaluation of efficacy, and the effective rate was 31.8% ; the effective rate for platinum-sensitive and platinum-resistant patients was 41.7% and 20.0% respectively; clinical benefit response rate was 57.1% ; the main toxicity was bone marrow depression and neurological toxicity, 15 cases occurred leukopenia （68.2%）, 16 cases occurred thrombocytopenia （ 72.7% ）, 71.4% patients occurred neurotoxicity and sensory abnormalities. Conclusion ： Treatment of recurrent advanced ovarian cancer with GemOx is effective, the toxicity is tolerable, and the quality of life was improved markedly.
出处
《海南医学院学报》
CAS
2009年第9期1068-1070,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020090142)~~
